Trial purpose
Cancer treatment
Tumor type
Upper gastrointestinal tract
Age
18 - 75
Clinical summary
Summary
Eligible participants will be randomised on a 2:1 basis based on minimisation and stratification by tumour stage, planned chemotherapy and institution, to one of two arms. Participants in the Experimental Arm will receive chemotherapy (12 week of mFOLFIRINOX and/or 12 additional weeks of gemcitabine/capecitabine), followed by radiation therapy (SBRT) to commence within 3 weeks of completing initial chemotherapy (40 Gray [GY] in 5 fractions over 2 weeks). Eligible participants will receive surgery 6 weeks post-completion of initial surgery. Patients who are not eligible for surgery will continue ongoing chemotherapy. Participants in the Active Comparator Arm will receive chemotherapy (12 weeks of mFOLFIRINOX or 12 additional weeks of gemcitabine/capecitabine). Eligible participants will receive surgery 6 weeks post-completion of initial surgery. Patients who are not eligible for surgery will continue ongoing chemotherapy.
Conditions
This trial is treating patients with pancreatic cancer
Eligibility
Inclusion
- Adults, aged between 18-75 years, with histological confirmation of pancreatic adenocarcinoma
-
Any of the following
- T3 (tumour >4 cm)
- Extrapancreatic extension
- Node positive (stage IIB)
- Borderline resectable pancreatic cancer, locally advanced pancreatic cancer
- Measurable disease according to RECIST v1.1
- ECOG performance status 0-1
- Adequate renal and haematological function
- Adequate hepatic function. Defined as bilirubin <1.5 X ULN (Upper Limit of Normal), AST + ALT <3.0 X ULN. In patients who have had a recent biliary drainage and whose bilirubin is descending, a value of ≤ 3 X N is acceptable
- Study treatment planned to start within 14 days of registration
- Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments
- Signed, written informed consent
Exclusion
- Tumour size greater than 70mm
- Prior abdominal radiotherapy
- Evidence of metastatic disease on baseline radiologic investigations
- History of another malignancy within 2 years prior to randomisation, except adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial transitional cell carcinoma of the bladder, or any Stage 1 endometrial carcinoma. Patients with a history of other malignancies are eligible if they have been continuously disease free for at least 2 years after definitive primary treatment
- Concurrent illness, including severe infection that may jeopardise the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety
- Neuroendocrine pancreatic carcinoma
- Life expectancy of less than 3 months
- Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must use a reliable means of contraception
- Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol
Inclusion
- Your cancer has not spread to other parts of the body (localised).
Exclusion
- You have been diagnosed with a prior or secondary type of cancer.
- You have certain types of non-cancer medical conditions.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria, and other criteria may apply for this trial. Ask your doctor about whether this trial could be right for you.
More information
Trial Identifiers
Information on this page is partially produced from ANZCTR, ClinicalTrials.gov *. View further details about this trial on the registry via the links below:
Trial sponsor
Australasian Gastro-Intestinal Trials Group (AGITG)
Scientific Title
A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease
Get Support
You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.
Know more about Cancer Connect
If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.
Get support
When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.
More info for carers